IC-ready brief · templated Proposal only
ACME Propose add to book confidence 77

Pharma · Nasdaq · as of 2026-09-22 · mandate northvale_quality_v3 · outside book panel

Executive summary

Recommendation
Propose adding ACME to the book · IC sizing · price contested.
Reason
Business quality cleared the house screen (80/100).
Analyst accepted the Phase 3 initiation catalyst on file (2026-08-12) as material to the case.
Tension
Main debate is valuation: about 41.7× earnings vs attractiveness 44/100 — outside the house comfort band (28×).
Open
Membership change proposed · nothing blocking on freeze or catalyst review.
IC-ready brief · score spine Proposal only

Score spine

Business quality 80 · Valuation attractiveness 44 · merge rule_quality_pass_price_contested

Analyst recommendation · accepted

Propose add ACME at committee-agreed size. Keep the valuation stretch explicit; do not scale the sleeve until Bull / Base assumptions are cited in the room.

Catalyst on file · accepted

phase3_initiation · MONITOR · page 2,841 · Q2 earnings call · 2026-08-12

“…Phase 3 cardiometabolic program… late-stage kickoff for the lead asset…”

Reported fundamentals

Revenue$12.4B Net income$2.1B Free cash flow$1.8B Gross margin75.0% Diluted EPS$4.82 P/E · FCF yield41.7× · 1.9%
IC-ready brief · debate Proposal only

Contestable points (for IC)

  • OPEN · AI read What are the underlying assumptions for the Bull and Base scenarios?
  • OPEN · AI read How does ACME’s capital efficiency compare to cardiometabolic peers?

Book proposals

Propose add · house book · target weight 1.50% · PROPOSAL_ONLY

Risks & watch triggers

  • AI read (quoted): “Valuation is fair on scenarios, but the P/E ratio suggests a demanding price.”
  • Current P/E sits above the house comfort band (28×).
  • Bull path implies significant growth and requires validation of enrollment pace.
  • Phase 3 readout timing remains the primary watch item for the sleeve.

Desk Q&A (accepted)

Q. Does Phase 3 change the propose-add?

A. No. Flag is MONITOR only. Propose-add stands; sizing stays with IC.

PROPOSAL_ONLY · not a trade instruction · as_of 2026-09-22

Book · weight schedule Proposal only

PROPOSAL_ONLY — does not change live weights until humans approve.

Mandate northvale_quality_v3

as of 2026-09-22 · base → multiplier → target · house book

Ticker Base × Target Action
ACME — 1.00 1.50% Propose add
HLX 2.40% 1.00 2.40% —
NVDX 3.10% 0.50 1.55% Trim
ORBC 1.80% 1.00 1.80% —
KLYN 2.05% 1.00 2.05% —
VREX 1.65% 1.00 1.65% —

Proposed changes this cycle

AddsACME · +1.50% TrimsNVDX · −1.55% Holds4 names · no change Net sleeve Δ−0.05 pp
Book · bounds & lineage Proposal only

Book overlay & multipliers

  • NVDX · multiplier 0.50 from book panel · trim proposed, not liquidated.
  • ACME · outside book panel · multiplier 1.00 · propose add at target.
  • Multipliers declared in code · may only downgrade · FAIL_CLOSED if unresolved.

Sleeve constraints

Single-name cap 3.0% · sector pharma sleeve within mandate band · no freeze on ACME or NVDX this as_of.

Capital moves only when humans approve · schedule is research classification only.

Lineage

Same score spine as name dossiers · merge rule_quality_pass_price_contested on ACME · reconstructible from versioned run artifacts.

Templated book schedule · PROPOSAL_ONLY · not a trade instruction · as_of 2026-09-22 · mandate northvale_quality_v3